Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Orthofix Medical Inc is a medical devices business based in the US. Orthofix Medical shares (OFIX) are listed on the NASDAQ and all prices are listed in US Dollars. Orthofix Medical employs 1,087 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $23.75 |
|---|---|
| 52-week range | $23.60 - $43.30 |
| 50-day moving average | $28.39 |
| 200-day moving average | $32.23 |
| Wall St. target price | $51.50 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.87 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $23.75 from 2022-06-28
| 1 week (2022-06-22) | -5.23% |
|---|---|
| 1 month (2022-05-27) | -12.97% |
| 3 months (2022-03-30) | -28.20% |
| 6 months (2021-12-30) | -23.34% |
| 1 year (2021-06-30) | -40.79% |
|---|---|
| 2 years (2020-06-30) | -25.78% |
| 3 years (2019-06-28) | 52.88 |
| 5 years (2017-06-29) | 46.21 |
Valuing Orthofix Medical stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Orthofix Medical's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Orthofix Medical's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 4.1. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Orthofix Medical's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Orthofix Medical's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $25.8 million.
The EBITDA is a measure of a Orthofix Medical's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $465.3 million |
|---|---|
| Gross profit TTM | $349.6 million |
| Return on assets TTM | -0.93% |
| Return on equity TTM | -10.73% |
| Profit margin | -7.96% |
| Book value | $16.91 |
| Market capitalisation | $487.2 million |
TTM: trailing 12 months
We're not expecting Orthofix Medical to pay a dividend over the next 12 months.
Over the last 12 months, Orthofix Medical's shares have ranged in value from as little as $23.6 up to $43.3. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Orthofix Medical's is 0.9664. This would suggest that Orthofix Medical's shares are less volatile than average (for this exchange).
Orthofix Medical Inc. operates as a medical device and biologics company in the United States, Italy, Germany, France, the United Kingdom, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion, as well as used as a therapeutic treatment for non-spinal and appendicular fractures. This segment also designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and a portfolio of products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions, as well as markets regenerative non-tissue biologic solutions derived from synthetic materials. The Global Orthopedics segment designs, develops, and markets orthopedic products that are used in fracture repair, deformity correction, and bone reconstruction procedures. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.